Prevalence of SARS-CoV-2 Omicron Sublineages and Spike Protein Mutations Conferring Resistance against Monoclonal Antibodies in a Swedish Cohort during …
J Haars, N Palanisamy, F Wallin, P Mölling, J Lindh… - Microorganisms, 2023 - mdpi.com
Monoclonal antibodies (mAbs) are an important treatment option for COVID-19 caused by
SARS-CoV-2, especially in immunosuppressed patients. However, this treatment option can …
SARS-CoV-2, especially in immunosuppressed patients. However, this treatment option can …
[HTML][HTML] Creation of Standardized Common Data Elements for Diagnostic Tests in Infectious Disease Studies: Semantic and Syntactic Mapping
C Stellmach, SM Hopff, T Jaenisch… - Journal of Medical …, 2024 - jmir.org
Background It is necessary to harmonize and standardize data variables used in case report
forms (CRFs) of clinical studies to facilitate the merging and sharing of the collected patient …
forms (CRFs) of clinical studies to facilitate the merging and sharing of the collected patient …
Anti-SARS-CoV-2 glyco-humanized polyclonal antibody XAV-19: phase II/III randomized placebo-controlled trial shows acceleration to recovery for mild to moderate …
G Poulakou, PJ Royer, N Evgeniev, G Evanno… - Frontiers in …, 2024 - frontiersin.org
Introduction XAV-19 is a glyco-humanized swine polyclonal antibody targeting SARS-CoV-2
with high neutralizing activity. The safety and clinical efficacy of XAV-19 were investigated in …
with high neutralizing activity. The safety and clinical efficacy of XAV-19 were investigated in …
[HTML][HTML] SARS-CoV-2 evolution during persistent infection in a CAR-T recipient shows an escape to both sotrovimab and T-cell responses
P Mazzetti, PG Spezia, AL Capria, G Freer… - Journal of Clinical …, 2023 - ncbi.nlm.nih.gov
Immunocompromised patients are at higher risk for severe COVID-19 due to higher baseline
viral loads and more common persistent infections. We present the case of a 58 years-old …
viral loads and more common persistent infections. We present the case of a 58 years-old …
Characterization of treatment resistance and viral kinetics in the setting of single-versus dual-active monoclonal antibodies against SARS-CoV-2
MC Choudhary, R Deo, TH Evering… - The Journal of …, 2024 - academic.oup.com
Background Monoclonal antibodies (mAbs) represent a crucial antiviral strategy for severe
acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, but it is unclear whether …
acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, but it is unclear whether …
A Robust Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)–Specific T-and B-Cell Response Is Associated With Early Viral Clearance in SARS-CoV …
M Vergouwe, JJ Biemond… - The Journal of …, 2024 - academic.oup.com
Background The immunological determinants of delayed viral clearance and intrahost viral
evolution that drive the development of new pathogenic virus strains in …
evolution that drive the development of new pathogenic virus strains in …
[HTML][HTML] Antibody drugs targeting SARS-CoV-2: Time for a rethink?
L Liang, B Wang, Q Zhang, S Zhang, S Zhang - Biomedicine & …, 2024 - Elsevier
Abstract The coronavirus disease 2019 (COVID-19) pandemic caused by severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2) heavily burdens human health. Multiple …
respiratory syndrome coronavirus 2 (SARS-CoV-2) heavily burdens human health. Multiple …
Serial Llama Immunization with Various SARS-CoV-2 RBD Variants Induces Broad Spectrum Virus-Neutralizing Nanobodies
PP Solodkov, AM Najakshin, NA Chikaev, SV Kulemzin… - Vaccines, 2024 - mdpi.com
The emergence of SARS-CoV-2 mutant variants has posed a significant challenge to both
the prevention and treatment of COVID-19 with anti-coronaviral neutralizing antibodies. The …
the prevention and treatment of COVID-19 with anti-coronaviral neutralizing antibodies. The …
Anti SARS-CoV-2 Monoclonal Antibodies in Pre-Exposure or Post-Exposure in No-or Weak Responder to Vaccine Kidney Transplant Recipients: Is One Strategy …
A Romero, C Laurent, L Lebourg, V Lemée, M Hanoy… - Viruses, 2024 - mdpi.com
Background: Kidney transplant recipients (KTRs) are likely to develop severe COVID-19 and
are less well-protected by vaccines than immunocompetent subjects. Thus, the use of …
are less well-protected by vaccines than immunocompetent subjects. Thus, the use of …
[HTML][HTML] Immunogenicity and reactogenicity of a first booster with BNT162b2 or full-dose mRNA-1273: A randomised VACCELERATE trial in adults≥ 75 years (EU …
JM Neuhann, J Stemler, AJ Carcas, J Frías-Iniesta… - Vaccine, 2023 - Elsevier
Background Vaccination remains crucial for protection against severe SARS-CoV-2
infection, especially for people of advanced age, however, optimal dosing regimens are as …
infection, especially for people of advanced age, however, optimal dosing regimens are as …